Abstract
We read with interest the manuscript entitled "Hepatic Manifestations in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome" by Eloseily et al,1 describing 4 patients with systemic juvenile idiopathic arthritis (sJIA) complicated by macrophage activation syndrome (MAS) and hepatic involvement and treated with emapalumab. We report our experience with this subgroup of patients, describing 2 cases treated at Meyer Children's Hospital in which patients experienced multiple hepatic relapses requiring a combined treatment approach.
